Sponsor-Investigators

Natalie Callander

BTCRC-MM21-528

Phase Ib/II Study of Selinexor in Combination with Carfilzomib, subcutaneous Isatuximab administered via investigational device, and Dexamethasone (SCID) for Patients with Relapsed and/or Relapsed Refractory Multiple Myeloma

Status

Cancer Types

Multiple Myeloma

Locations

University of Wisconsin Carbone Cancer Center